John Parkinson

As the summer celebrations begin, food safety remains vital to everyone.

In a human challenge, an investigational spray, Neumifil (HEX17), manufactured by Pneumagen, reported its results at the recent American Thoracic Society meeting.

Study results on Vowst were presented at the recent DDW conference.

A Michigan farmworker who had regular contact with livestock was confirmed to have contracted the virus.

A newer strategic approach combined with existing treatments are together trying to reduce incidence rates and cure people of HCV, but barriers to treatment remain, and often leave people outside the continuum of care.

Public health officials have confirmed 5 cases since mid-March with a separate case associated with a grocery store employee.

The novel vaccine, ARCT-154, is a self-amplifying messenger RNA (sa-mRNA) vaccine and now has the first published demonstration of clinical efficacy for this type of vaccine.

Both the World Health Organization and FDA have now recommended this particular set of viruses be left off influenza vaccines for the 2024-2025 respiratory virus season. A new study points to further evidence of their extinction.

A study shows the definitive presence of the virus long-term in individuals and could point to lingering symptoms and the possibility of Long COVID.

A new study demonstrates that for last year’s respiratory season, the difference in death rates were still much higher for COVID-19, but the gap closed significantly from the year before.

North Carolina’s senate voted to repeal the health exemption of the existing mask wearing law, thus disallowing any exceptions for people to wear a mask across the state.

Dennis Petragnani has battled gastrointestinal issues for years, and he shares what he sees as the transformation of change in the public and medical community talking about C diff and therapies around it, and the kinship with people he has met through the Peggy Lillis Foundation.

The federal agency gave the nod to Roche’s human papillomavirus (HPV) self-collection and gives women the ability to gather their own sample in a health care setting, which can then be sent off for lab results.

The FDA announces the voluntary recall of Hy-Vee Cream Cheese Spread due to the potential contamination of Salmonella.

In the second installment of the discussion around the Equity in Antimicrobial Stewardship Efforts (EASE), the codevelopers of this novel framework discuss how to move forward with interventions and measuring success around them.

The new Equity in Antimicrobial Stewardship Efforts (EASE) is a comprehensive set of priorities designed to overcome inequities and address the challenges with prescribing practices within the minoritized populations.

The federal agency said that due to administrative constraints, they will not complete the review of mRNA-1345 by the PDUFA date of May 12.

The investigational vaccine, mRNA-1345, developed for seniors has its FDA PDUFA date in a few days.

In patients with Clostridium difficile infection (CDI), ibezapolstat was shown to have similar results to a standard of care therapy.

New data from a World Health Organization (WHO) repository illustrates the treatment challenges during the acute phase of the pandemic.

According to the latest Centers for Disease Control and Prevention (CDC) data, these strains have increased in incidence rates, and now account for nearly a third of all US cases.

Hospital grades released by Leapfrog reviews state and now metro areas for safety and patient satisfaction.

In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).

A Centers for Disease Control and Prevention (CDC) investigator offers insights into their investigation of customers receiving vampire facials (a spa cosmetic procedure) and contracting the virus afterwards.

This cephalosporin antibiotic was examined against colistin-susceptible gram-negative infections.

A large study being presented at ESCMID shows the therapy was associated with a significantly lower mortality at 14-days and 28-days.

A novel approach using this emerging technology looks to interfere with antibiotic resistance expression and reduce this global health issue.

A study finds that despite the development of some new agents for highly-resistant pathogens, prescribers are reluctant to utilize these therapies.

New data reinforced the safety and tolerability profile of this antiretroviral therapy for this patient population who are virologically suppressed.

Pivmecillinam (Pivya) was given the nod from the federal agency, and is indicated for female adults with uncomplicated urinary tract infections (UTIs) caused by susceptible isolates of Escherichia coli, Proteus mirabilis and Staphylococcus saprophyticus.